Physician profile
Thomas Elder Kosh
NPI 1881061208
$11,022.56
in general payments reported to CMS, 2019-2025
60 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $1,243 · 2023: $2,387 · 2024: $4,109 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,657 · Long Term Medical Supply Or Device Loan: $2,165 · Education: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,657.03 |
| Long Term Medical Supply Or Device Loan | $2,165.10 |
| Education | $706.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,497.67 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $859.02 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $775.52 | 2022-2025 | Erleada, Darzalex, Imbruvica |
| Daiichi Sankyo INC. | $773.79 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Pfizer INC. | $372.19 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $363.71 | 2024-2025 | Opdivo, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $349.67 | 2022-2025 | |
| Gilead Sciences, INC. | $251.03 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $241.43 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Sobi, INC | $237.94 | 2023-2025 | |
| Pharmaessentia USA Corporation | $232.50 | 2023-2025 | Besremi |
| Tempus Ai, INC | $216.79 | 2024-2025 | Xt Cdx |
| Celgene Corporation | $191.87 | 2022-2025 | Reblozyl, Pomalyst |
| Adaptive Biotechnologies Corporation | $190.17 | 2023-2024 | Clonoseq |
| Emmaus Medical, INC. | $186.07 | 2022-2024 | Endari |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.48 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $177.21 | 2022-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $166.65 | 2023-2025 | Xpovio |
| Astellas Pharma US INC | $166.42 | 2024 | Vyloy, Padcev, Xtandi |
| Jazz Pharmaceuticals INC. | $157.25 | 2023-2025 | |
| Incyte Corporation | $152.75 | 2024 | Monjuvi, Jakafi |
| Medtronic, INC. | $148.55 | 2022 | |
| Spinal Elements, INC. | $145.47 | 2021 | |
| Aveo Pharmaceuticals, INC. | $142.61 | 2022-2024 | |
| Genzyme Corporation | $123.43 | 2023-2024 | |
| Glaxosmithkline, LLC. | $119.94 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $118.55 | 2022-2023 | |
| Emd Serono, INC. | $107.31 | 2022-2024 | Bavencio |
| Amgen INC. | $94.48 | 2022-2023 | Lumakras |
| Stemline Therapeutics INC. | $87.49 | 2023-2025 | Orserdu |
| Adc Therapeutics America, INC. | $87.00 | 2023-2025 | |
| Kci USA, INC. | $86.48 | 2021 | |
| Geron Corporation | $75.02 | 2025 | Rytelo |
| Shield Therapeutics INC | $71.47 | 2024 | |
| Tersera Therapeutics LLC | $69.79 | 2022-2025 | Xermelo, Zoladex |
| Regeneron Healthcare Solutions, INC. | $67.53 | 2023-2024 | Libtayo |
| Genentech USA, INC. | $59.88 | 2024 | Tecentriq Hybreza, Polivy, Lunsumio |
| Puma Biotechnology, INC. | $52.13 | 2022-2025 | |
| Sirtex Medical INC | $48.73 | 2024 | Sir-Spheres Microspheres |
| Genmab U.S., INC. | $46.98 | 2025 | Tivdak |
| Eisai INC. | $45.51 | 2022-2024 | |
| Seagen INC. | $42.39 | 2022 | |
| Mirati Therapeutics, INC. | $41.29 | 2023-2024 | Krazati |
| Morphosys, US INC. | $37.85 | 2023-2024 | Monjuvi |
| Caris Mpi, INC. | $33.81 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $32.56 | 2024 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $28.63 | 2023 | |
| Pharmacosmos Therapeutics INC. | $25.18 | 2024 | Monoferric |
| Syndax Pharmaceuticals, INC. | $25.17 | 2025 | |
| Array Biopharma INC | $22.95 | 2024 | Braftovi, Lorbrena, Xalkori |
| Taiho Oncology, INC. | $21.81 | 2025 | |
| Cti Biopharma Corp. | $21.72 | 2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $21.30 | 2023 | Rezlidhia, Tavalisse |
| Dendreon Pharmaceuticals LLC | $20.85 | 2023 | Provenge |
| Springworks Therapeutics, INC. | $19.06 | 2025 | Gomekli |
| Sanara Medtech INC. | $18.93 | 2021 | |
| Servier Pharmaceuticals LLC | $18.36 | 2023 | |
| Exelixis INC. | $17.83 | 2025 | Cabometyx |
| Acrotech Biopharma INC. | $17.15 | 2025 | Beleodaq |
| Myriad Genetic Laboratories, INC. | $15.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.